{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:11:01Z","timestamp":1775121061174,"version":"3.50.1"},"reference-count":50,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: The optimal timing of adjuvant chemotherapy after cytoreductive surgery in epithelial ovarian cancer remains uncertain, and perioperative wound-healing responses may transiently create a pro-tumorigenic and drug-resistant microenvironment. This study aimed to characterize time-dependent wound-induced transcriptomic alterations and to identify pharmacologic agents capable of reversing these responses. Methods: An ID8 murine ovarian cancer model was used to compare no treatment, anesthesia alone, and anesthesia plus surgical wounding mimicking futile laparotomy. Tumors were collected at baseline, 1 day (T1), 1 week (T2), and 2 weeks (T3) after intervention. RNA sequencing was performed, and wound-specific differentially expressed genes (WsDEGs) were defined by excluding anesthesia- and progression-related signatures. Functional enrichment analyses were conducted, followed by transcriptome-based drug repurposing using the REMEDY platform to identify compounds predicted to reverse wound-induced gene expression profiles. Results: Surgical wounding significantly increased tumor burden at T1. Transcriptomic analyses revealed distinct, time-dependent wound-associated programs. At T1, WsDEGs were enriched in inflammatory signaling, coagulation, angiogenesis, and immune cell migration, with Vorinostat and Homoharringtonine identified as top candidates to counteract these signatures. At T2, pathways related to cell survival, adhesion, and morphogenesis predominated, with LY-2090314, Artesunate, and Birinapant emerging as potential modulators. At T3, cell-cycle regulation and lipid metabolic pathways were dominant, and Fulvestrant, Atorvastatin, Imatinib, and ABT-737 were predicted to inhibit these processes. Conclusions: Perioperative surgical wounding induces dynamic, stage-specific transcriptomic programs that may promote ovarian cancer progression and alter drug responsiveness. These findings support time-adapted perioperative pharmacologic strategies to optimize postoperative cancer therapy.<\/jats:p>","DOI":"10.3390\/pharmaceutics18040413","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:41:03Z","timestamp":1774878063000},"page":"413","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Time-Resolved Transcriptomic Profiling of Surgical Wounds Identifies Stage-Specific Therapeutic Targets for Residual Ovarian Cancer"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1174-1344","authenticated-orcid":false,"given":"Seongyun","family":"Lim","sequence":"first","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Jae","family":"Cho","sequence":"additional","affiliation":[{"name":"Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06531, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8342-0040","authenticated-orcid":false,"given":"Myeong-Seon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University School of Medicine, Seoul 14353, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Joo","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Yoon","family":"Ryu","sequence":"additional","affiliation":[{"name":"Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06531, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Ryoung","family":"Hwang","sequence":"additional","affiliation":[{"name":"Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06531, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9112-5436","authenticated-orcid":false,"given":"Ju-Yeon","family":"Choi","sequence":"additional","affiliation":[{"name":"Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06531, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0471-6236","authenticated-orcid":false,"given":"Mahesh Chandra","family":"Patra","sequence":"additional","affiliation":[{"name":"Drug Development Team, ARONTIER Inc., Seoul 06735, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1696-5934","authenticated-orcid":false,"given":"Mohamed El-Agamy","family":"Farh","sequence":"additional","affiliation":[{"name":"Drug Development Team, ARONTIER Inc., Seoul 06735, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Insuk","family":"Sohn","sequence":"additional","affiliation":[{"name":"Drug Development Team, ARONTIER Inc., Seoul 06735, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6110-4909","authenticated-orcid":false,"given":"Jeong-Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5902-9877","authenticated-orcid":false,"given":"Yoo-Young","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jogoh.2019.03.017","article-title":"Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Long text of the Joint French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa. Part 1: Diagnostic exploration and staging, surgery, perioperative care, and pathology","volume":"48","author":"Lavoue","year":"2019","journal-title":"J. Gynecol. Obstet. Hum. Reprod."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","article-title":"NCCN Guidelines\u00ae Insights: Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer, Version 3.2024: Featured Updates to the NCCN Guidelines","volume":"22","author":"Liu","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2016.09.015","article-title":"The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients\u2014An analysis of NRG Oncology\/Gynecologic Oncology Group trials","volume":"143","author":"Chan","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100143","DOI":"10.1016\/j.esmorw.2025.100143","article-title":"Time to adjuvant chemotherapy and overall survival in advanced-stage ovarian cancer patients in England: A population-based retrospective cohort study","volume":"8","author":"Steventon","year":"2025","journal-title":"ESMO Real World Data Digit. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ijgo.12653","article-title":"Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer","volume":"143","author":"Lee","year":"2018","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_8","first-page":"1307","article-title":"Tumor size, sensitivity to therapy, and design of treatment schedules","volume":"61","author":"Norton","year":"1977","journal-title":"Cancer Treat. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Gu, Y., Zhou, G., Tang, X., Shen, F., Ding, J., and Hua, K. (2023). The biological roles of CD24 in ovarian cancer: Old story, but new tales. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1183285"},{"key":"ref_10","first-page":"1488","article-title":"Influence of the Interval between Primary Tumor Removal and Chemotherapy on Kinetics and Growth of Metastases1","volume":"43","author":"Fisher","year":"1983","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13048-018-0428-6","article-title":"Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model","volume":"11","author":"Lee","year":"2018","journal-title":"J. Ovarian Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Hingorani, D.V., Lippert, C.N., Crisp, J.L., Savariar, E.N., Hasselmann, J.P.C., Kuo, C., Nguyen, Q.T., Tsien, R.Y., Whitney, M.A., and Ellies, L.G. (2018). Impact of MMP-2 and MMP-9 enzyme activity on wound healing, tumor growth and RACPP cleavage. PLoS ONE, 13.","DOI":"10.1101\/327791"},{"key":"ref_13","first-page":"3177","article-title":"The effect of surgical wound on ovarian carcinoma growth in an animal model","volume":"33","author":"Lee","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1006\/jsre.2002.6444","article-title":"Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats","volume":"105","author":"Roman","year":"2002","journal-title":"J. Surg. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13048-021-00895-w","article-title":"A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin","volume":"14","author":"Clark","year":"2021","journal-title":"J. Ovarian Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2014.56.3106","article-title":"Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: An analysis of GOG 182","volume":"33","author":"Horowitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_19","first-page":"101","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma","volume":"42","author":"Griffiths","year":"1975","journal-title":"Natl. Cancer Inst. Monogr."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Rocher, G., Gaillard, T., Uzan, C., Collinet, P., Bolze, P.A., Ballester, M., Bendifallah, S., Ouldamer, L., Touboul, C., and Huchon, C. (2021). Does Time-to-Chemotherapy after Primary Complete Macroscopic Cytoreductive Surgery Influence Prognosis for Patients with Epithelial Ovarian Cancer? A Study of the FRANCOGYN Group. J. Clin. Med., 10.","DOI":"10.3390\/jcm10051058"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13048-021-00801-4","article-title":"Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: A retrospective study","volume":"14","author":"Wang","year":"2021","journal-title":"J. Ovarian Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Farolfi, A., Petracci, E., Gurioli, G., Tedaldi, G., Casanova, C., Arcangeli, V., Amadori, A., Rosati, M., Stefanetti, M., and Burgio, S.L. (2023). Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1221096"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1158\/1055-9965.EPI-14-1279-T","article-title":"Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort","volume":"24","author":"Ose","year":"2015","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/aje\/kwt098","article-title":"A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor \u03b1 receptor 2 levels and risk of ovarian cancer","volume":"178","author":"Poole","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ygyno.2018.11.034","article-title":"Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: A retrospective study","volume":"152","author":"Nie","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1470-2045(18)30373-5","article-title":"Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS\/NHSII): A cohort study","volume":"19","author":"Merritt","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/jnci\/djac239","article-title":"Common analgesics and ovarian cancer survival: The Ovarian cancer Prognosis And Lifestyle (OPAL) Study","volume":"115","author":"Majidi","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41586-025-08626-7","article-title":"Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity","volume":"640","author":"Yang","year":"2025","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-15-0461","article-title":"A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients","volume":"21","author":"Guo","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1093\/annonc\/mds107","article-title":"A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: The DoCaCel study","volume":"23","author":"Reyners","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1158\/1078-0432.CCR-24-3368","article-title":"Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study","volume":"31","author":"Banerjee","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2227","article-title":"Vorinostat","volume":"6","author":"Grant","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00280-015-2813-9","article-title":"Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer","volume":"76","author":"Matulonis","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3892\/ol.2017.5630","article-title":"Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells","volume":"13","author":"Ma","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40001-024-01856-x","article-title":"Homoharringtonine: Updated insights into its efficacy in hematological malignancies, diverse cancers and other biomedical applications","volume":"29","author":"Khatua","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Guo, S., Bai, X., Shi, S., Deng, Y., Kang, X., and An, H. (2021). TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222010930"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"15663","DOI":"10.1038\/s41598-022-19621-7","article-title":"Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel","volume":"12","author":"Plett","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/15384047.2019.1595283","article-title":"Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses","volume":"20","author":"Sahin","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1158\/1535-7163.MCT-11-0534","article-title":"Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM\/ATR damage response in cancer cells","volume":"10","author":"Berdelle","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-012-2352-6","article-title":"Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-\u03b1-independent mechanism","volume":"137","author":"Allensworth","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Chang, Y.-C., and Cheung, C.H.A. (2021). An Updated Review of Smac Mimetics, LCL161, Birinapant, and GDC-0152 in Cancer Treatment. Appl. Sci., 11.","DOI":"10.3390\/app11010335"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.3816\/CBC.2005.s.008","article-title":"The history and mechanism of action of fulvestrant","volume":"6","author":"Carlson","year":"2005","journal-title":"Clin. Breast Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ygyno.2013.07.099","article-title":"Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer","volume":"131","author":"Argenta","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1541-7786.MCR-21-0456","article-title":"Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair","volume":"19","author":"Dow","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"ref_45","first-page":"2478","article-title":"Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro","volume":"7","author":"Jones","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1002\/cam4.1131","article-title":"Small cell lung carcinoma cell line screen of etoposide\/carboplatin plus a third agent","volume":"6","author":"Teicher","year":"2017","journal-title":"Cancer Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mc.22474","article-title":"Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate","volume":"56","author":"Greenshields","year":"2017","journal-title":"Mol. Carcinog."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Noonan, A.M., Cousins, A., Anderson, D., Zeligs, K.P., Bunch, K., Hernandez, L., Shibuya, Y., Goldlust, I.S., Guha, R., and Ferrer, M. (2020). Matrix Drug Screen Identifies Synergistic Drug Combinations to Augment SMAC Mimetic Activity in Ovarian Cancer. Cancers, 12.","DOI":"10.3390\/cancers12123784"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3892\/ijo.2022.5325","article-title":"Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers","volume":"60","author":"Singh","year":"2022","journal-title":"Int. J. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: A review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol. Med."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/4\/413\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:00:25Z","timestamp":1775116825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/4\/413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["pharmaceutics18040413"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18040413","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]}}}